Re: $HZNP getting unusual large call blocks
Geri, the company is really pushing the Krystexxa growth story, yet the SEL-212 P2 data appears to be more effective (lower, sustained uric acid levels over 4 weeks). Do you view that as a threat to Krystexxa? Perhaps it is suppressing shares since (Jerome shared a while back) more data is due in the near future. Also re: Krystexxa from Q2 CC: "At the same time, we are now assuming a lower KRYSTEXXA average net realized price beginning in the second half primarily based on our assumption that the U.S. Government's Health Resource and Services Administration's Final Rule on 340B drug ceiling price is implemented on October 1 as currently scheduled."
In my opinion, investing in HZNP (of which I have a long position) is more a gamble at present. It is certainly a very long term play if you believe in management's story/vision. You still think they get to $2B by 2020?